ArticleThe Journal of clinical investigation2026

Osimertinib activates a TGF-β2-dependent secretory program that drives lung adenocarcinoma progression.

Madhurima Ghosh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.